• Ricardo Valentini, José Fernández, Dardo Riveros, Fernando Pálizas, Jorge Solimano, Pablo Saúl, Juan Medina, Viviana Falasco, María Laura Dupont, Julia Laviano, Florencia Fornillo, Daniela Maymó, Daniel Gotta, Alfredo Martínez, Pablo Bonvehí, and Juan Dupont.
• Departamento de Medicina, CEMIC, Buenos Aires, Argentina. E-mail: rvalentini@cemic.edu.ar.
• Medicina (B Aires). 2020 Jan 1; 80 Suppl 6: 9179-17.

AbstractThe COVID-19 pandemic presented high mortality from its beginning, without effective treatment for seriously ill patients. Build on the experience in Argentine hemorrhagic fever with convalescent plasma, we incorporated 90 patients with COVID-19, of which 87 were evaluable, into a multicenter study. We collected 397 plasma donations from 278 convalescent donors. Patients received plasma with an IgG concentration of 0.7-0.8 (measured by Abbott chemiluminescence) for every 10 kg of body weight. Survival during the first 28 days was the primary objective; 77% were male, age 54 ± 15.6 y/o (range 27-85), body mass index 29.7 ± 4.4; hypertension 39% and diabetes 20.7%; 19.5% had an immunosuppressive condition, 23% were health workers. Plasma was administered to 55 (63%) on spontaneous breathing with oxygen supplementation (mainly oxygen mask with reservoir bag in 80%), and to 32 patients (37%) on mechanical ventilation. The 28-day survival rate was 80%; 91% in patients infused on spontaneous breathing and 63% in those on mechanical ventilation (p = 0.0002). There was a significant improvement in the WHO pneumonia clinical scale at 7 and 14 days, and in PaO2 / FiO2, ferritin and LDH, in the week post-infusion. We observed an episode of circulatory volume overload and a febrile reaction, both mild. Convalescent plasma infusions are feasible, safe, and potentially effective, especially before requiring mechanical ventilation. They are an attractive clinical option for treating severe forms of COVID-19 until other effective therapies become available.

16 keywords...

hide…